Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Equity Ratio (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Equity Ratio for 6 consecutive years, with 0.76 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio changed N/A year-over-year to 0.76, compared with a TTM value of 0.76 through Sep 2025, changed N/A, and an annual FY2024 reading of 0.79, changed 0.34% over the prior year.
  • Equity Ratio was 0.76 for Q3 2025 at Cytek Biosciences, roughly flat from 0.77 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.89 in Q3 2021 and bottomed at 0.05 in Q2 2021.
  • Average Equity Ratio over 5 years is 0.76, with a median of 0.81 recorded in 2023.
  • Peak annual rise in Equity Ratio hit 1848.83% in 2022, while the deepest fall reached 6.38% in 2022.
  • Year by year, Equity Ratio stood at 0.87 in 2021, then fell by 6.38% to 0.82 in 2022, then dropped by 2.96% to 0.79 in 2023, then decreased by 0.34% to 0.79 in 2024, then dropped by 3.45% to 0.76 in 2025.
  • Business Quant data shows Equity Ratio for CTKB at 0.76 in Q3 2025, 0.77 in Q2 2025, and 0.79 in Q4 2024.